Johnson & Johnson
Johnson & Johnson Reports Q4 2024 Financial Results and Pipeline Progress
Summary
Johnson & Johnson reported Q4 2024 financial results with reported sales growth of 5.3% to $22.5 billion and adjusted earnings per share (EPS) of $2.04. Operational sales grew by 6.7%, driven by Innovative Medicine and MedTech segments. The company also made significant progress in its pipeline, with approvals and initiation of submissions for several products. Johnson & Johnson provided 2025 guidance with expected operational sales growth of 2.5% to 3.5%.
Profitelligence Alerts
Get alerts for JNJ
Be first to know when Johnson & Johnson files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About Johnson & Johnson
Johnson & Johnson is a multinational corporation engaged in the research, development, production, and sale of a broad range of healthcare products. Primarily known for its pharmaceuticals, medical devices, and consumer health products, Johnson & Johnson has a significant presence in the global healthcare industry. It develops medications for a variety of fields such as immunology, oncology, neurology, infectious diseases, and vaccines. The company also produces a wide array of medical devices for surgery, orthopedics, and cardiovascular health. In addition to pharmaceuticals, Johnson & Johnson is renowned for its consumer health products, including baby care, skin and hair care, wound care, and over-the-counter pharmaceuticals, with well-recognized brands like Band-Aid, Tylenol, and Neutrogena. Operating globally, the corporation's extensive portfolio and commitment to healthcare innovation make it a pivotal player in the industry, ensuring it remains influential in addressing worldwide health challenges and advancing medical technology.
Official SEC Documents
Advertisement